Sunday 18 October 2026
Export IMMP’s income statement to Excel — free account
Prima BioMed Ltd
IMMP Healthcare Biotechnology
Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025. Revenue growth for three consecutive years.
3.20
0.01
−0.31%
Follow IMMP
| Dec '25 | Dec '24 | Dec '23 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | — |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | — | ||
ROIC |
0.00% | 0.00% | 0.00% | — | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | — | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(42.34) | (31.71) | (35.13) | — | |
Capital Expenditures |
(0.13) | (0.07) | (0.07) | — | |
| Other line items | |||||
Cash ROIC |
(32.48%) | (14.63%) | (24.57%) | — | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026